FDA Advisory Panel Favors Extended Use of Xeljanz by Certain Ulcerative Colitis Patients

FDA Advisory Panel Favors Extended Use of Xeljanz by Certain Ulcerative Colitis Patients
An advisory arm of the U.S. Food and Drug Administration (FDA) gave two positive recommendations to Pfizer’s supplemental New Drug Application, seeking FDA approval for extended use of Xeljanz (tofacitinib) by certain adult patients with moderately to severely active ulcerative colitis (UC). The Gastrointestinal Drugs Advisory Committee (GIDAC) voted unanimously in favor (15–0) to extend the induction dosage

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *